Mya C. Schiess

Faculty, Staff and Student Publications Publication Date 12-1-2025 Journal Movement Disorders PubMedCentral® Posted Date 9-1-2025 PubMedCentral® Full Text Version Post-print Abstract Background: Neuroinflammation contributes to Parkinson's disease (PD) progression and motor dysfunction. Allogeneic human mesenchymal stem cells (allo-hMSCs) may reduce neuroinflammation and improve motor symptoms.

Since the 1960s, when Carlsson, Hornykiewicz, Cotzias, and Yahr identified nigral dopamine deficits in Parkinson's disease (PD) and introduced dopamine replacement therapy, numerous pharmacological and neuromodulation treatments have effectively alleviated motor symptoms.1 In regenerative medicine, PD has been a key target for cell-based therapies aimed at symptom improvement and disease modification, with various approaches explored clinically over the past decades.2 Stem cell therapy for PD...

Introduction Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is the first-line surgical treatment for Parkinson's disease (PD), it can effectively improve Parkinson's disease patients' motor and non-motor symptoms (1, 2), reduce motor fluctuations, reduce dopaminergic drug use and adverse drug reactions, and improve patients' quality of life (3–5).